JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Innoviva Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

18.48 -1.02

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.11

Max

18.52

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-67M

-47M

Pardavimai

-3.2M

89M

P/E

Sektoriaus vid.

51.694

40.048

Pelno marža

-52.559

Darbuotojai

127

EBITDA

-63M

-27M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+116.48% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-12M

1.2B

Ankstesnė atidarymo kaina

19.5

Ankstesnė uždarymo kaina

18.48

Naujienos nuotaikos

By Acuity

34%

66%

112 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-04 21:42; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025-08-04 21:21; UTC

Uždarbis
Pagrindinės rinkos jėgos

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025-08-04 20:45; UTC

Uždarbis

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025-08-04 19:15; UTC

Pagrindinės rinkos jėgos

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025-08-04 23:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-04 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Fed Stimulus Hopes

2025-08-04 23:28; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-08-04 23:28; UTC

Rinkos pokalbiai

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025-08-04 21:30; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 21:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025-08-04 21:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 20:25; UTC

Rinkos pokalbiai

India Hits Back Over Russian Oil Purchases -- Market Talk

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss $938M >RIG

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss/Shr $1.06 >RIG

2025-08-04 20:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025-08-04 20:15; UTC

Uždarbis

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025-08-04 20:13; UTC

Uždarbis

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025-08-04 20:09; UTC

Uždarbis

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025-08-04 20:06; UTC

Uždarbis

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025-08-04 19:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025-08-04 19:28; UTC

Rinkos pokalbiai

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025-08-04 19:07; UTC

Rinkos pokalbiai

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025-08-04 18:27; UTC

Rinkos pokalbiai

Gold Climbs on Rate Cut Speculation -- Market Talk

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

116.48% į viršų

12 mėnesių prognozė

Vidutinis 40.33 USD  116.48%

Aukščiausias 55 USD

Žemiausias 26 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

18.57 / 18.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

112 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.